New CAR T-Cell therapy takes on Hard-to-Treat myeloma

NCT ID NCT07399444

Not yet recruiting Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new treatment called LVIVO-TaVec400 for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to better attack cancer cells. The study will enroll 38 adults and primarily check for safety and the right dose, while also measuring how long the modified cells last in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LVIVO-TaVec400 (a CAR T-cell therapy made from the patient's own immune cells)
What this could lead to: If it works, this could point toward a new treatment option for patients with multiple myeloma that has not responded to other therapies.
What could go wrong: This is a very early, small trial (38 people) focused on safety and dosing. It may not lead to an effective treatment, and CAR T-cell therapies can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA (MM)

Contacts and locations

Locations

Beijing GoBroad Boren Hospital

Beijing, China
Henan Cancer Hospital

Zhengzhou, Henan, China
Institute of Hematology & Blood Diseases Hospital

Tianjin, China
The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.